Agoracom Blog Home

Posts Tagged ‘#smallcapstocks’

ThreeD Capital Inc. $IDK.ca Announces Completion of Oversubscribed Private Placement to Raise $1,155,000

Posted by AGORACOM-JC at 4:12 PM on Tuesday, October 24th, 2017

Threed capital

  • Announced that it has completed a non-brokered private placement
  • Issued 11,550,000 units at a price of $0.10 per Unit to raise aggregate gross proceeds of $1,155,000
  • Each Unit consists of one common share of the Company and one common share purchase warrant

TORONTO, Oct. 24, 2017 – ThreeD Capital Inc. (the “Company”) (CSE:IDK) is pleased to announce that it has completed a non-brokered private placement (the “Offering”) announced on October 16, 2017, pursuant to which it has issued 11,550,000 units (“Units”) at a price of $0.10 per Unit to raise aggregate gross proceeds of $1,155,000.  Each Unit consists of one common share of the Company and one common share purchase warrant (a “Warrant”).  Each Warrant entitles the holder thereof to acquire one additional common share of the Company at an exercise price of $0.15 until October 24, 2020.

All securities issued and issuable in connection with the Offering are subject to a statutory hold period expiring on February 25, 2018.

Insiders of the Company subscribed for an aggregate of 1,250,000 Units pursuant to the Offering.  Proceeds of the Offering will be used for investment purposes and general working capital.

About ThreeD Capital Inc.

ThreeD Capital Inc. is a publicly- traded Canadian-based venture capital firm focused on opportunistic investments in companies in the resource, technology, biotechnology, and blockchain markets.

For further information: Gerry Feldman, CPA, CA Chief Financial Officer and Corporate Secretary
[email protected] Phone: 416-606-7655

FEATURE: Tetra Bio-Pharma $TBP.ca – Only Pharma Company To Have Clinical Studies for Smoked #Marijuana #MMJ #CBD

Posted by AGORACOM-JC at 11:38 AM on Tuesday, October 24th, 2017

WHY TETRA BIO-PHARMA?

 

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected

INTERVIEW: PyroGenesis $PYR.ca Discusses Completion of Ramp-Up Phase of 1st Plasma Atomization System, 3 NDAs being negotiated with multinational aircraft engine manufacturers

Posted by AGORACOM-JC at 9:22 AM on Tuesday, October 24th, 2017

Peeks Social $PEEK.ca to Accept #Bitcoin and Other #Cryptocurrencies

Posted by AGORACOM-JC at 8:02 AM on Tuesday, October 24th, 2017

Peeks large

  • Will begin accepting Bitcoin amongst other cryptocurrencies as a payment option within Peeks Social
  • Technical planning is complete and the Company is now confident that it can integrate Bitcoin and other cryptocurrencies in a manner that will be financially beneficial to the Company

TORONTO, Oct. 24, 2017 – Peeks Social Ltd. (TSXV:PEEK) (OTCQB:PKSLF) (“Peeks Social” or “the Company”) announces that the Peeks Social platform will begin accepting Bitcoin amongst other cryptocurrencies as a payment option within Peeks Social.

Technical planning is complete and the Company is now confident that it can integrate Bitcoin and other cryptocurrencies in a manner that will be financially beneficial to the Company and provide users with a wider variety of payment options. Since cryptocurrency purchases are not subject to payment processing fees, the addition of cryptocurrency transactions are expected to reduce the aggregate payment processing fees currently associated with processing payments within the Peeks Social platform. In-app payments are subject to a 30% payment processing fees from their respective app stores.  Additionally, cryptocurrency payments are expected to increase the number of purchases in Peeks Social as a result of providing users with increased anonymity when making purchases within the service.

Cryptocurrency payment options will be available on www.peeks.com in the upcoming weeks. The Peeks Social app can be downloaded in either the Apple or Google app stores, or by visiting www.peeks.com.

For further information, please contact:

Peeks Social Ltd.                                       Mark Itwaru                 David Vinokurov Chairman & Chief Executive Officer                 Director Investor Relations 416-815-7000 x303                 416-716-9281 [email protected]                 [email protected]Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this Release.

Forward-Looking statements:

The information and statements in this news release contain certain forward-looking information relating to the development and deployment of certain functionalities of the Peeks Social service, including assumptions regarding third party adoption and use. This forward-looking information is subject to certain risks and uncertainties and may be based on assumptions that could cause actual results to differ materially from those anticipated or implied in the forward-looking information. Peeks Social Ltd.’s forward-looking information is expressly qualified in its entirety by this cautionary statement. Except as required by law, Peeks Social Ltd. undertakes no obligation to publicly update or revise any forward-looking information.

Are you an investor in Richmont Mines $RIC.ca ? Check out the recent acquisition by Monarques $MQR.ca

Posted by AGORACOM-JC at 4:17 PM on Monday, October 23rd, 2017

Monarquesgold hub large

Why Monarques Gold?

  • A gold producer with the Beaufor Mine (gold production of 19,562 ounces in 2016; source Richmont 2016 annual report)
  • Located in one of the best mining jurisdictions in Canada.
  • A large portfolio of mining assets, including the Beaufor Mine, two mills (Camflo and Beacon), two advanced projects (Wasamac and Croinor Gold) and eight exploration projects covering more than 240 km2 in the Abitibi region.
  • Upside potential and leverage to the gold price with the Wasamac project.
  • NI 43-101 proven and probable reserves of 162,790 ounces of gold, measured and indicated resources of 1.76 million ounces and inferred resources of 1.67 million ounces (see table below).
  • Over 150 highly experienced, qualified employees will join the Monarques team.
  • A strong financial position, with over $12 million in cash and cash equivalents.

American Creek $AMK.ca encounters high grade Au/Ag at Treaty Creek north of, and in the same system as Seabridge Gold $SA $SEA.ca KSM project

Posted by AGORACOM-JC at 2:49 PM on Monday, October 23rd, 2017

AMK: TSX-V, OTCBB: ACKRF

RECENT HIGHLIGHTS

  • Additional gold discovery of 5.1m of 9.57 g/t gold from 249.35m to 254.45m Read More
  • Tudor Has Discovered a New Gold Zone at Treaty Creek: 110 M of 0.909 g/t Gold, Upper 316 M of Hole Yet to Be Assayed
  • Specimens from the Electrum property average 27,092 gm/tonne silver and 248 gm/tonne gold. Read More
  • Tudor has now completed the previously announced Magnetotelluric survey and has commenced drilling Read More
  • Hole CB-16-03 returned 0.526 g/t gold over 629.7 meters
  • Included within this wide 629.7 meter interval is 338 meters of 0.70 g/t gold
  • Also included 54 meters (from 88 to 142 meters) of 1.117 g/t gold and 122 meters of 0.965 g/t gold

View Presentation

PyroGenesis $PYR.ca Announces Completion of Ramp-Up Phase of 1st Plasma Atomization System

Posted by AGORACOM-JC at 8:42 AM on Monday, October 23rd, 2017

Pyr header 1

During the ramp-up, the following were also achieved:

  • Six Non-Disclosure Agreements signed with distributors and 3D printer manufacturers
  • Three NDAs being negotiated with multinational aircraft engine manufacturers, at their request
  • Exclusive distributorship under negotiation in Asia
  • Received six sample orders for metal powder, of which five have been delivered to date
  • Developed new, potentially game changing, intellectual property; Patent applications progressing as expected

MONTREAL, QUEBEC–(Oct. 23, 2017) – PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX VENTURE:PYR)(OTCQB:PYRNF), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and plasma torch products, announces today that it has successfully completed the ramp-up phase of its first plasma atomization system.

During the ramp-up, the following were also achieved:

  • Six (6) Non-Disclosure Agreements (“NDA”) signed with distributors and 3D printer manufacturers
  • Three (3) NDAs being negotiated with multinational aircraft engine manufacturers, at their request
  • Exclusive distributorship under negotiation in Asia
  • Received six (6) sample orders for metal powder, of which five (5) have been delivered to date
  • Adjusted process for other metal powders (i.e. Inconel)
  • Developed new, potentially game changing, intellectual property; Patent applications progressing as expected

Mr. P. Peter Pascali, President and CEO of PyroGenesis, provides an overview of today’s announcement in the following Q&A format. The questions, for the most part, are derived from inquiries received from investors, analysts, and potential customers:

Q: You announce today that ramp-up is complete? What does that mean exactly?

A: It means that we are open for business. By announcing the end of ramp-up, the plasma atomization reactor is fully functional, and ready to operate 24/7. We have added a second shift in anticipation of large scale commercial orders. The feedback so far is that our powders are of exceptional quality and, given our capacity for innovation, we offer extremely competitive pricing. As previously noted, we are already in discussion with numerous players in the field. 

Q. In terms of your sales strategy, do you plan on targeting metal 3D printer manufacturers, end users such as GE, distributors, or all the above?

A. As noted above, we have signed six (6) NDAs with both distributors and 3D printer manufacturers and three (3) NDAs are currently being negotiated with multinational aircraft engine manufacturers.

PyroGenesis’ strategy in the beginning of 2016, when we first announced that we were reentering the business of producing the very same powders we once produced for ourselves and the biomedical industry, was simply to be a credible second supplier. It only made good business sense for companies to have a second supplier for a vital feedstock such as titanium powders, and we wanted to fill that role.

Approximately one year ago, GE announced its acquisition of Arcam and, by default, AP&C. This acquisition, in our opinion, effectively introduced a supply chain risk in Additive Manufacturing (“AM”), despite AP&C’s willingness to still sell powders into the marketplace. We have found that end-users, and metal 3D printer manufacturers alike, want to make their supply chain more robust. We believe that as a result of GE’s acquisition of Arcam/AP&C, we are seeing a particular interest from GE’s competitors. We are in the process of negotiating at least three (3) NDAs with multinational aircraft engine manufacturers after having concluded at least another five (5) with metal 3D printer manufacturers. This activity, we believe, not only underscores, but validates our previously identified concerns regarding the supply chain.

So, with that as background, and to answer your question, we are positioning ourselves to be a dominant metal powder supplier to anyone in the industry with a need for small, spherical, uniform metal powders, of exceptional characteristics, whose particle size can be varied depending on the need. 

Of interest, is that we are not so much targeting a specific group as we have been targeted by them. We currently have ongoing discussions with end users, distributors, and printer manufactures.

Q. What kind of feedback have you received from the sample powder orders you have shipped?

A. The feedback we have been getting since being on-line has all been positive and beyond what we anticipated. I cannot stress enough that we never expected to receive sample orders during ramp-up. The take away should not just be that we received these sample orders during ramp-up, but that we have also signed a number of NDAs with credible players.

To recap, PyroGenesis has received six (6) unique sample orders, including one sample order for both our Grade 23 and Grade 5 MIM cut. Of these sample orders, we have currently shipped five (5), and the majority of these only in the past two (2) months. To date, we have not had any negative feedback.

Q. Do you plan on selling spot orders, or entering into a partnership / joint venture, or an exclusive sales agreement?

A. As discussed above, our original strategy was to sell spot orders, but given the strategic importance of GE’s acquisition of Arcam, and the concerns it has created with respect to powder supply, we believe that the market is now more interested in long term arrangements such as partnerships, joint ventures, and exclusivity agreements as opposed to buying spot orders as needed.

Q. In your press release dated Sept 18, 2017, you mentioned that, “…to the best of our knowledge, we know of no other company that offers commercial quantities of Ti-6Al-4V Grade 23 MIM cut…”. Does this suggest there won’t be a significant demand for MIM powder?

A. Absolutely not. It’s quite the opposite in fact.

We see demand coming from two areas:

First, with respect to AM, the MIM cut powder is being considered as a feed to making parts in quantity; essentially targeting high volume rather than high value manufacturing. This is what Desktop Metal, Markforged, 3DEO and Digital Metal are doing. These companies have effectively gained prominence very recently.

Spherical Ti64 grade 23, and grade 5, MIM cut powder (i.e. less than 25 microns) is not easy to produce. Our ability to supply these powders in commercial quantities, which can be produced with little or no waste, is enabling the industry.

Second, beyond AM, specifically in metal injection molding, end users have traditionally been trading flowability for part density. With PyroGenesis’ recent innovations, these end users can now have both flowability, with an extremely dense part, by sourcing PyroGenesis’ MIM cut powder.

As you can see, PyroGenesis is in effect enabling two (2) markets with our new plasma-based atomization system; namely for Additive Manufacturing and Metal Injection Molding. As such, in conclusion, we expect the demand for our MIM powder to exceed our most aggressive forecast model. We believe we are uniquely positioned to become the largest supplier of MIM cut powders to this industry should the anticipated explosive demand be realized.

Q. So, bottom line, you envision high demand for your MIM cut powder?

A. Yes. As I said, we believe that as 3D printing evolves, and new printers are developed, there will be an increased demand for different metal powder particle size cuts. We believe that the growth in demand for MIM cut powders by companies such as DeskTop Metal, 3DEO, Markforged, and Digital Metal will continue to grow. Additionally, we also anticipate a portion of our MIM cut powders to be sold to Metal Injection Molding companies.

Our ability to produce very narrow size cuts in significant volumes, with little to no waste, will not only allow us to address an explosive demand for MIM cut, but for any particular particle range, thereby enabling metal printers to evolve unrestricted by supply constraints. 

Q. How do you see the demand for the other size cuts of powder (i.e. SLS and EBM cuts) evolving? Are you concerned at all that other non-powder-bed AM methods, such as directed energy deposition, could become more widely adopted and impact the demand for powder feedstock?

A. Each AM method has its own targeted niche application. From SLS, to EBM, to Ink Jet, to Directed Energy Deposition, they each have targeted applications. EBM for example is excellent for, and quite widely adopted by, medical implants (such as hip joints). Each method offers a unique solution which can range from crude parts production that are large and require considerable post machining and processing, to repair parts, to others that are almost in their final form. Although AM has clear advantages over conventional manufacturing, we believe that it will remain a complimentary and parallel manufacturing method to conventional manufacturing. This being said, AM is finding considerable acceptance, and adoption, across many industries. As such, we see the AM method continuing to grow at current double-digit growth rates for the foreseeable future. 

Furthermore, we are not concerned that other non-powder-bed AM methods, such as Directed Energy Deposition, could become more widely adopted and impact the demand for powder feedstock. Directed Energy Deposition is an excellent solution for producing large parts that are very crude in finish and require considerable post machining and processing. This solution could be a choice for certain applications; however, for certain other applications, that require intricate internal details, or an almost finished build (near net shape), this method falls short or simply cannot achieve the desired results. Directed Energy Deposition in fact is derived from the welding industry and has been around for a considerable amount of time. We see the growth in AM coming from “net shape parts”, and in fact, are seeing a considerable amount of demand and growth coming from the finer size cut powders (exactly where we have been focusing in anticipation of this demand). More and more clients are requesting a high purity fine powder, and this is exactly where PyroGenesis’ new plasma-based process excels.

Q. The market would like some clarification – how did PyroGenesis get into this business of producing and selling powders?

A. PyroGenesis originally invented Plasma Atomization to address an internal need for small spherical titanium powders which were required for a project we were working on for NATO, i.e. developing light weight armor. It was difficult to find small spherical titanium powders of the quality we needed, and when we did, they were very expensive. This was well before there was any significant demand for these powders by metal 3D printers.

To make a long story short, we invented Plasma Atomization (and actually coined the term in our original patent application) to make small spherical powders for ourselves, not realizing that these powders had a use in the biomedical industry. The biomedical industry liked how our powders flowed like water and compacted tightly. The industry immediately found a use for them in the production of titanium implants (ex. titanium knee and hip replacements). Our first commercial biomedical sale was to a company called Stryker Corporation (the relationship of which was transferred to AP&C, who we believe, can still count them as one of their important customers today). 

When the program to develop lightweight armor came to an end, the biomedical industry would not take up all of our powder production, which is the reason PyroGenesis decided to get out of the business of powder production and, to this end, reached an arrangement wherein AP&C could continue the business subject to, amongst other things, a non-compete clause which ended in 2012. AP&C (a former division of Raymor Industries) sought creditor protection in 2009. When AP&C eventually came out of creditor protection, metal 3D printers started to have a need for the exact titanium powders that PyroGenesis’ Plasma Atomization system produced, and which AP&C was trying to commercialize. Arcam AB, a manufacturer of metal 3D printers, became a client of AP&C and eventually bought AP&C in 2013. Since that time, Arcam has done an amazing job of industrializing the process and AP&C, under Arcam, has become one of the dominant suppliers of titanium powders to metal 3D printers.

Q. Will your newly developed ability to control particle size distributions allow you to significantly differentiate yourself from your competition in terms of price?

A. We believed that we could differentiate ourselves from our competition in terms of price, before our newly developed ability to control particle size distribution was a consideration; our recent developments only solidifies/amplifies this advantage.

Separately, PyroGenesis announces today that it has signed an agreement with Crescendo Communications, LLP (“Crescendo”), effective November 1, 2017, for certain capital market strategic advisory services, specifically, to increase the Company’s market awareness amongst investors, with a particular emphasis on those in the United States (the “Agreement”).

In consideration of the services to be provided, the Company has agreed to pay Crescendo a monthly retainer fee of $6,000, with the first two months due ($12,000) upon signing of the Agreement. The Company may terminate the Agreement with Crescendo, at any time after December 31, 2017, by providing thirty (30) days’ written notice.

Crescendo does not have any interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest.

“We are pleased to announce that we have selected Crescendo to help increase PyroGenesis’ profile within the financial community as well as enhance the visibility of our product lines,” said Mr. Pascali. “We believe Crescendo’s methodologies fit well with the Company’s strategy to increase awareness within the investment community.”

In addition, and given the numerous inquiries on the topic, Mr. Pascali would like to take this opportunity to confirm that he has been a net buyer of PyroGenesis’ shares over the past few months as reflected in his public filings. “I have been adding to my ownership of PyroGenesis over the past few months,” said Mr. Pascali. “My intention is to continue to do so, as a net buyer, over the next few months as well.”

Additional information on the Company is available on SEDAR at www.sedar.com.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. PyroGenesis provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Its core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Its operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace (Ticker Symbol: PYRNF). For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

Rodayna Kafal
VP, Investor Relations and Communications
(514) 937-0002
[email protected] or [email protected]

Peeks Social $PEEK.ca Launches Brand Advertising Program

Posted by AGORACOM-JC at 8:25 AM on Friday, October 20th, 2017

Peeks large

  • As part of the ongoing advancement of the Peeks Social service, an advertising platform integration is now complete
  • Peeks Social ad platform was purpose built to facilitate the sale of all ad units available for sale on broadcast and digital platforms

TORONTO, Oct. 20, 2017 — Peeks Social Ltd. (TSX-V:PEEK) (OTCQB:PKSLF) (“Peeks Social” or the “Company”) is pleased to announce that as part of the ongoing advancement of the Peeks Social service, an advertising platform integration is now complete. The Peeks Social ad platform was purpose built to facilitate the sale of all ad units available for sale on broadcast and digital platforms.  Specifically, the Peeks Social ad platform facilitates the sale of product placement ads, cost per impression (“CPM”) ads, cost per action (“CPA”) ads, onscreen overlays, and affiliate marketing programs.

The Peeks Social ad platform interacts with the OfferBox so that ads can result in direct sales. The Peeks Social proprietary ad platform allows advertisers to target ads based on a wide variety of viewer demographics including location, age, gender, and individual tastes.

The platform will be launching multiple ad campaigns through aggregate and direct brand partners ranging from in-stream sponsors, CPM, and CPA advertisers.  Some of the brands and offers that will be available include eHarmony, Fandango DermaVia, Namaste, and others.

As previously announced on September 14, 2017, the Company has now released two of three new advertising and sales features and is on schedule to release the final component of the full OfferBox alongside 50+ brands that will be available to streamers on the Peeks Social service upon release. This will include brands that are participating in paid advertising campaigns.

Stock Option Grant

The Company also announced that in accordance with the Company’s Stock Option Plan, it has granted 500,000 options to Board Member Jim Westlake, and 75,000 options to Director of Investor Relations David Vinokurov.  The options vest over a 12-month period as to 20% immediately and 20% every three months thereafter.  The options are exercisable at $0.60 and expire five years from the date of grant.

For further information, please contact:

Peeks Social Ltd.                   Mark Itwaru       David Vinokurov Chairman & Chief Executive Officer        Director Investor Relations 647-992-7727       416-716-9281  [email protected]        [email protected]
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this Release.

Forward-Looking statements:

The information and statements in this news release contain certain forward-looking information relating to the development, functionality, and deployment of certain functionalities of the Peeks Social livestreaming product, including assumptions regarding third party adoption and use. This forward-looking information is subject to certain risks and uncertainties and may be based on assumptions that could cause actual results to differ materially from those anticipated or implied in the forward-looking information. Peeks Social Ltd.’s forward-looking information is expressly qualified in its entirety by this cautionary statement. Except as required by law, Peeks Social Ltd. undertakes no obligation to publicly update or revise any forward-looking information.

Tartisan Resources Corp. $TTC.ca to Acquire Canadian Arrow Mines Limited $CRO.ca

Posted by AGORACOM-JC at 8:11 AM on Friday, October 20th, 2017

Tartisan logo copy

  • Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited by way of a court-approved plan of arrangement
  • Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan

TORONTO, Oct. 20, 2017 – Canadian Arrow Mines Limited (TSX.V:CRO) – (“Canadian Arrow”) announces that a definitive arrangement agreement (the “Agreement”) has been signed with Tartisan Resources Corp. (CSE: TTC) – (“Tartisan”) whereby Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited (“Canadian Arrow”) by way of a court-approved plan of arrangement (the “Arrangement”) in accordance with the Business Corporations Act (Ontario) in exchange for common shares in the capital of Tartisan.

Pursuant to the terms of the Agreement, Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan. Additionally, Tartisan would issue up to 4,500,000 common shares of Tartisan to settle Canadian Arrow debt pursuant to debt conversion agreements with various Canadian Arrow creditors. Certain lock up provisions are included in the Debt Conversion Agreements. Tartisan has also agreed to pay the transaction related expenses of Canadian Arrow.

The proposed transaction provides Canadian Arrow shareholders with liquidity, sustaining capital and an opportunity to participate in the potential upside of Tartisan.

The board of directors of Canadian Arrow (the “Canadian Arrow Board”) has approved the Arrangement and the entering into of the Arrangement Agreement and has determined to recommend that shareholders of Canadian Arrow vote in favour of the Arrangement. Completion of the Arrangement is subject to customary closing conditions, including approval of the Ontario Superior Court of Justice (Commercial List), the approval of holders of not less than 66 2/3% of the holders of Canadian Arrow Shares voted at a special meeting of Canadian Arrow shareholders that will be called to approve the Arrangement (the “Special Meeting”) as well as majority of the minority approval as required under applicable Canadian securities laws. The Arrangement is also subject to the approval of the TSX Venture Exchange, the Canadian Securities Exchange and all applicable regulatory authorities, as well other conditions typical for a transaction of this nature.

The terms of the Arrangement will be summarized in an information circular of Canadian Arrow (the “Circular”) that is anticipated to be mailed to the shareholders of Canadian Arrow in connection with the Special Meeting which is expected to be held in early January 2018. Canadian Arrow has received from Harris Capital Corporation an opinion that the Arrangement consideration is fair, from a financial point of view, to the shareholders of Canadian Arrow, and retained Fogler Rubinoff LLP as its legal counsel. Robert M. Isles is acting as legal counsel to Tartisan. A copy of the Arrangement Agreement, the Circular and related documents will be filed with the Canadian regulatory authorities and will be available for review under Canadian Arrow’s SEDAR profile at www.sedar.com.

The Agreement contains customary non-solicitation provisions which are subject to Canadian Arrow’s right to consider and accept a superior proposal subject to a matching right in favour of Tartisan. In the event that the Arrangement is not completed as a result of a superior proposal or for other certain specified circumstances, Canadian Arrow will pay Tartisan a termination fee of $100,000.

The Arrangement constitutes a “business combination” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) for Canadian Arrow as Canadian Arrow is indebted to certain of its directors and such indebtedness will be settled through the issuance of common shares of Tartisan in connection with the closing of the Arrangement. The indebtedness of Dean MacEachern is approximately $9,000, the indebtedness of Kim Tyler is approximately $5,000 and the indebtedness of George Pirie is approximately $20,000. Although Canadian Arrow does not consider the amounts of such indebtedness to be material the fact that such indebtedness is being satisfied through the issuance of common shares of Tartisan in connection with the completion of the Arrangement means that the Arrangement is considered to be a Business Combination for the purposes of MI 61-101. Canadian Arrow is relying on the formal valuation exemption in section 4.4(a) of MI 61-101, on the basis that no securities of Canadian Arrow are listed on the Toronto Stock Exchange or other specified markets. Canadian Arrow will seek the requisite approvals of the Arrangement from its shareholders at the Special Meeting.

If the Arrangement is completed, the common shares of Canadian Arrow will be delisted from the TSX Venture Exchange.

None of the securities to be issued pursuant to the Arrangement Agreement have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issued in the Arrangement are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

About Tartisan Resources Corp.

Tartisan Resources Corp. is a Canadian mineral exploration and development company focused on project generation of precious and base metal properties. Tartisan owns a 100% stake in the Don Pancho Zinc-Lead-Silver Project just 9 km from Trevali’s Santander Mine and owns a 100% stake in the Ichuna Copper-Silver Project contiguous to Buenaventura’s San Gabriel Property. Tartisan Resources portfolio also includes an equity stake (6 million shares and 3 million warrants @ 40 cents) in Eloro Resources Ltd. (TSX.V:ELO). Tartisan Resources Corp. common shares are listed on the Canadian Securities Exchange and is a Member of the CSE Composite Index (CSE:TTC). There are currently 73,052,443 shares outstanding (90,145,827 fully diluted).

About Canadian Arrow Mines Limited

Canadian Arrow is an experienced exploration and mine operating team that is focussed on acquiring and developing economically viable nickel sulphide deposits near existing infrastructure. Canadian Arrow operates in north-western Ontario, near the towns of Kenora and Dryden. The company’s main asset is the Kenbridge Nickel Project, a nickel-copper sulphide deposit containing over 98 million lbs of nickel in Measured & Indicated Resources. The deposit is equipped with a 620m shaft and has never been mined.

Additional information about Canadian Arrow can be found at the company’s website at www.canadianarrowmines.com or on SEDAR at www.sedar.com.

Forward Looking Information

Certain information contained in this news release constitutes forward looking information. All information other than information of historical fact is forward looking information. The use of any of the words “intend”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “would”, “believe”, “predict” and “potential” and similar expressions are intended to identify forward looking information. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward looking information. No assurance can be given that this information will prove to be correct and such forward looking information included in this news release should not be unduly relied upon.

The forward looking information provided in this news release is based upon a number of material factors and assumptions including, without limitation: (a) that the Arrangement will be completed in the timelines and on the terms currently anticipated; (b) that all necessary CSE, TSXV, court and regulatory approvals will be obtained on the timelines and in the manner currently anticipated; (c) that all necessary Shareholder approvals will be obtained; and (d) general assumptions respecting the business and operations of both Canadian Arrow and Tartisan, including that each business will continue to operate in a manner consistent with past practice and pursuant to certain industry and market conditions.

Readers are cautioned that the foregoing list of risks, uncertainties and assumptions are not exhaustive.

The forward looking information included in this news release is expressly qualified by this cautionary statement and is made as of the date of this news release. Neither Canadian Arrow nor Tartisan undertake any obligation to publicly update or revise any forward looking information except as required by applicable securities laws.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Canadian Arrow Mines Limited

Tetra Bio-Pharma $TBP.ca Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

Posted by AGORACOM-JC at 8:07 AM on Thursday, October 19th, 2017

Tbp large new

  • Announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).
  • Will be responsible for the medical information of Rx Princepsâ„¢ and will be educating the medical community about the benefits of this controlled and standardized blend of medical cannabis

OTTAWA, ONTARIO–(Oct. 19, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).

Dr. Jourdain will be responsible for the medical information of Rx Princepsâ„¢ and will be educating the medical community about the benefits of this controlled and standardized blend of medical cannabis. Dr. Jourdain has extensive training and knowledge in pharmacology and neuroscience and is a critical addition to the Tetra team. An important part of his role will be to support the sales of Rx Princepsâ„¢ through New Brunswick and the Maritimes, as well as in Quebec, by presenting the safety, pharmacokinetic, and pharmacodynamic data gathered in Tetra’s Phase 1 clinical trial of PPP001.

“The addition of Dr. Jourdain demonstrates our strategic intention to position Tetra Bio-Pharma as the leader in the medical cannabis market. Bringing an individual with the level of scientific knowledge and expertise of Dr. Jourdain shows our organization’s commitment to the medical community; they can continue to count on Tetra Bio-Pharma as a credible and professional source of information for their practice and their patients. We are looking forward to further developing relationships with opinion leaders in the field as we continue to advance our clinical program and work on bringing new drug alternatives for patients and their treating healthcare professionals.” states Dr. Guy Chamberland, Chief Scientific Officer of Tetra.

Tetra also reveals today its new logo and corporate image, thereby aligning its corporate image with its medical strategy. The evolution of The Company’s image highlights Tetra’s objective to be the reference for the medical community in prescribed cannabinoids’ safety, efficacy, and quality. Tetra is focused on bringing to the ACMPR market the highest quality medical cannabis; the Company remains committed to receive the first drug approval from Health Canada’s Therapeutic Products Directorate for a medical cannabis drug.

About RxPrincepsâ„¢:

Rx Princepsâ„¢ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princepsâ„¢ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001.

Rx Princepsâ„¢ will soon be available across Canada, through our partner Aphria’s customer service, for patients who have a prescription from their physicians.

About Dr. Vincent Jourdain, Ph.D.:

Dr. V. Jourdain, Ph.D. is a graduate from the pharmacy program at Laval University in Quebec City, where he specialized in neurological disorders. He completed his postdoctoral training at the Feinstein Institute for Medical Research in New York. He used brain imaging to study metabolic and neurovascular changes in Parkinson’s disease and pharmacologically-induced side effects. Dr. Jourdain possesses a broad, yet specialized, knowledge in Neurology and accumulated close to 10 years of experience in basic and clinical research. He published over 15 peer-review publications and won several awards and scholarships.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210